How to buy NextCure stock | 10.11

NextCure, Inc is a biotechnology business based in the US. NextCure shares (NXTC) are listed on the NASDAQ and all prices are listed in US Dollars. NextCure employs 69 staff and has a trailing 12-month revenue of around USD$24.4 million.

How to buy shares in NextCure

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for NextCure. Find the stock by name or ticker symbol: NXTC. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until NextCure reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$10.11, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of NextCure, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of NextCure. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted NextCure's share price?

Since the stock market crash in March caused by coronavirus, NextCure's share price has had significant negative movement.

Its last market close was USD$10.11, which is 79.46% down on its pre-crash value of USD$49.22 and 179.82% down on the lowest point reached during the March crash when the shares fell as low as USD$28.29.

If you had bought USD$1,000 worth of NextCure shares at the start of February 2020, those shares would have been worth USD$742.39 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$232.23.

NextCure share price

Use our graph to track the performance of NXTC stocks over time.

NextCure shares at a glance

• Key figures

Information last updated 2020-11-17.

Latest market close	USD$10.11
52-week range	USD$7.91 - USD$70.98
50-day moving average	USD$10.5774
200-day moving average	USD$16.2178
Wall St. target price	USD$23.67
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-1.917

Buy NextCure shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy NextCure stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of NextCure, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

NextCure price performance over time

Historical closes compared with the close of $10.11 from 2020-11-16

1 week (2020-11-17)	0.70%
1 month (2020-10-23)	-18.66%
3 months (2020-08-24)	13.47%
6 months (2020-05-22)	-69.46%

1 year (2019-11-22)	-72.53%
2 years (2018-11-20)	N/A
3 years (2017-11-20)	N/A
5 years (2015-11-20)	N/A

NextCure financials

Revenue TTM	USD$24.4 million
Gross profit TTM	USD$-27,869,000
Return on assets TTM	-8.87%
Return on equity TTM	-13.42%
Profit margin	-131.52%
Book value	$11.154
Market capitalisation	USD$278.6 million

TTM: trailing 12 months

Shorting NextCure shares

There are currently 1.9 million NextCure shares held short by investors – that's known as NextCure's "short interest". This figure is 7% up from 1.8 million last month.

There are a few different ways that this level of interest in shorting NextCure shares can be evaluated.

NextCure's "short interest ratio" (SIR)

NextCure's "short interest ratio" (SIR) is the quantity of NextCure shares currently shorted divided by the average quantity of NextCure shares traded daily (recently around 410742.11663067). NextCure's SIR currently stands at 4.63. In other words for every 100,000 NextCure shares traded daily on the market, roughly 4630 shares are currently held short.

However NextCure's short interest can also be evaluated against the total number of NextCure shares, or, against the total number of tradable NextCure shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NextCure's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 NextCure shares in existence, roughly 70 shares are currently held short) or 0.0737% of the tradable shares (for every 100,000 tradable NextCure shares, roughly 74 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against NextCure.

Find out more about how you can short NextCure stock.

NextCure share dividends

We're not expecting NextCure to pay a dividend over the next 12 months.

NextCure overview

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase 2 clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the B7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. NextCure, Inc. has a license agreement with Yale University; and a research and development collaboration with Eli Lilly and Company. The company was founded in 2015 and is headquartered in Beltsville, Maryland.

Frequently asked questions

• What percentage of NextCure is owned by insiders or institutions?

  Currently 14.333% of NextCure shares are held by insiders and 74.969% by institutions.

• How many people work for NextCure?

  Latest data suggests 69 work at NextCure.

• When does the fiscal year end for NextCure?

  NextCure's fiscal year ends in December.

• Where is NextCure based?

  NextCure's address is: 9000 Virginia Manor Road, Beltsville, MD, United States, 20705

• What is NextCure's ISIN number?

  NextCure's international securities identification number is: US65343E1082

• What is NextCure's CUSIP number?

  NextCure's Committee on Uniform Securities Identification Procedures number is: 65343E108